Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C95024
http://purl.obolibrary.org/obo/NCIT_C95024
|
|---|---|
| Preferred Name | Racotumomab |
| Definitions |
An anti-idiotype murine monoclonal antibody (MoAb) specific to P3 MoAb with anti-metastatic effect. Racotumomab binds to the idiotype region of P3 MoAb and functionally mimics the three-dimensional structure of N-glycolyl ceramides of mono-sialyl lactose, the antigenic target of P3. As a result, this anti-idiotype antibody may stimulate the host immune system to elicit humoral and cellular immune responses against tumor cells expressing NeuGc-GM3 gangliosides, which are expressed in a wide variety of tumor cells.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An anti-idiotype murine monoclonal antibody (MoAb) specific to P3 MoAb with anti-metastatic effect. Racotumomab binds to the idiotype region of P3 MoAb and functionally mimics the three-dimensional structure of N-glycolyl ceramides of mono-sialyl lactose, the antigenic target of P3. As a result, this anti-idiotype antibody may stimulate the host immune system to elicit humoral and cellular immune responses against tumor cells expressing NeuGc-GM3 gangliosides, which are expressed in a wide variety of tumor cells. |
|---|---|
| prefLabel | Racotumomab
|
| label | Racotumomab
|
| PDQ_Closed_Trial_Search_ID | 689646
|
| code | C95024
|
| prefixIRI | NCIT:C95024
|
| in_subset | |
| Preferred_Name | Racotumomab
|
| FDA_UNII_Code | 52G405U1E5
|
| Contributing_Source | FDA
|
| Maps_To | Racotumomab
|
| CAS_Registry | 946832-34-4
|
| NCI_Drug_Dictionary_ID | 689646
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 689646
|
| Semantic_Type |
Pharmacologic Substance
Immunologic Factor
|
| UMLS_CUI | C2986854
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |